Lundbeck wins Neoprofen case against FTC
This article was originally published in Scrip
Executive Summary
In a closely watched antitrust case, a US federal court has ruled against the US Federal Trade Commission (FTC) in its 2008 challenge of Ovation/Lundbeck's acquisition of Neoprofen (ibuprofen lysine injectable) from Abbott. The regulator alleged that the deal was to gain a monopoly on the only two drugs approved to treat patent ductus arteriosus (PDA), a serious and potentially deadly congenital heart defect affecting premature babies.